In connection with its recent acquisition of Sairiyo Therapeutics, the company has secured an exclusive license to develop and commercialize a novel oral formulation
PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) announced it has reached an agreement with Southwest Research Institute (SwRI) to initiate clinical and non-clinical manufacturing of Cepharanthine for the company’s rare cancer and infectious diseases programs.
In connection with the company’s recent acquisition of Sairiyo Therapeutics Inc, PharmaDrug has secured an exclusive license from SwRI to develop and commercialize a novel oral formulation of Cepharanthine.
Cepharanthine is a natural product and has been approved for more than 70 years in Japan for a variety of acute and chronic diseases. The natural product has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, antiviral and antiparasitic.